EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY-NC-ND 4.0

Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis

Robert Spiera iD, Masataka Kuwana iD, Dinesh Khanna iD, Laura Hummers iD, Tracy M Frech iD, Wendy Stevens, Marco Matucci-Cerinic, Suzanne Kafaja, Oliver Distler iD, Jae-Bum Jun iD, Yair Levy, Piotr Leszcyzński und 20 weitere

Arthritis & Rheumatology · 2023

DOI: 10.1002/art.42510 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Arthritis & Rheumatology, 2023. Verfasst von Robert Spiera und 31 weiteren Autor:innen. Beteiligte Einrichtung: Weill Cornell Medical College, New York, New York. Hauptthemen laut MEDLINE: Scleroderma, Diffuse, Scleroderma, Systemic. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This phase 3 study was undertaken to investigate the efficacy and safety of lenabasum, a cannabinoid type 2 receptor agonist, in patients with diffuse cutaneous systemic sclerosis (dcSSc).

Methods

A multinational double‐blind study was conducted in 365 dcSSc patients who were randomized and dosed 1:1:1 with lenabasum 20 mg, lenabasum 5 mg, or placebo, each twice daily and added to background treatments, including immunosuppressive therapies (IST).

Results

The primary end point, the American College of Rheumatology combined response index in dcSSc (CRISS) at week 52 for lenabasum 20 mg twice a day versus placebo, was not met, with CRISS score of 0.888 versus 0.887 ( P = 0.4972, using mixed models repeated measures [MMRM]). The change in the modified Rodnan skin thickness score (MRSS) at week 52 for lenabasum 20 mg twice a day versus placebo was −6.7 versus −8.1 ( P = 0.1183, using MMRM). Prespecified analyses showed higher CRISS scores, greater improvement in MRSS, and lower decline in forced vital capacity in patients on background mycophenolate and those who were taking IST for ≤1 year. No deaths or excess in serious or severe adverse events related to lenabasum were observed.

Conclusion

A benefit of lenabasum in dcSSc was not demonstrated. Most patients were treated with background IST, and treatment with mycophenolate mofetil in particular was associated with better outcomes. These findings support the use of IST in the treatment of dcSSc and highlight the challenge of demonstrating a treatment effect when investigational treatment is added to standard of care IST. These findings have relevance to trial design in SSc, as well as to clinical care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Scleroderma, DiffuseScleroderma, SystemicHumansCannabinoid Receptor AgonistsTreatment OutcomeSeverity of Illness IndexDronabinolSkin

Substanzen

lenabasumCannabinoid Receptor AgonistsDronabinol

Autor:innen und Institutionen

  • Weill Cornell Medical College, New York, New York.
  • Nippon Medical School Graduate School of Medicine, Tokyo, Japan.
  • University of Michigan, Ann Arbor.
  • John Hopkins University School of Medicine, Baltimore, Maryland.
  • University of Utah and Salt Lake City VA Health Care System, Salt Lake City, Utah.
  • St. Vincent's Hospital, Melbourne, Victoria, Australia.

ORCID-Profile: Robert Spiera, Masataka Kuwana, Dinesh Khanna, Laura Hummers, Tracy M Frech, Oliver Distler, Jae-Bum Jun, Jessica Gordon, Eun Bong Lee, Maureen Mayes, Christopher P Denton

Zitieren

APA

Spiera, R., Kuwana, M., Khanna, D., Hummers, L., Frech, T. M., Stevens, W., Matucci-Cerinic, M., Kafaja, S., Distler, O., Jun, J. B., Levy, Y., Leszcyzński, P., Gordon, J., Steen, V., Lee, E. B., Jankowski, T., Litinsky, I., Chung, L., Hsu, V., …, & RESOLVE-1 Study Group (2023). Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis. Arthritis & Rheumatology. https://doi.org/10.1002/art.42510

Vancouver

Spiera R, Kuwana M, Khanna D, Hummers L, Frech TM, Stevens W, et al. Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis. Arthritis & Rheumatology. 2023. doi:10.1002/art.42510

BibTeX
@article{Spiera2023,
  author = {Spiera, Robert and Kuwana, Masataka and Khanna, Dinesh and Hummers, Laura and Frech, Tracy M and Stevens, Wendy and Matucci-Cerinic, Marco and Kafaja, Suzanne and Distler, Oliver and Jun, Jae-Bum and Levy, Yair and Leszcyzński, Piotr and Gordon, Jessica and Steen, Virginia and Lee, Eun Bong and Jankowski, Tomasz and Litinsky, Irena and Chung, Lorina and Hsu, Vivien and Mayes, Maureen and Sandorfi, Nora and Simms, Robert W and Finzel, Stephanie and de Vries-Bouwstra, Jeska and Constantine, Scott and Dgetluck, Nancy and Dinh, Quinn and Bloom, Bradley J and Furst, Daniel E and White, Barbara and Denton, Christopher P and RESOLVE-1 Study Group, RESOLVE-1 Study Group},
  title = {Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis},
  journal = {Arthritis & Rheumatology},
  year = {2023},
  doi = {10.1002/art.42510}
}
Kostenlos starten →